Evidence map›Paper›PMID 25404192›Full record

Trial reportJournal of the American Heart Association2014

Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.

David C Wheeler, Gerard M London, Patrick S Parfrey, Geoffrey A Block, Ricardo Correa-Rotter, Bastian Dehmel, Tilman B Drüeke, Jürgen Floege, Yumi Kubo, Kenneth W Mahaffey and 7 more

Erratum issued Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00345839 (EValuation Of Cinacalcet Hydrochloride), which is not on this map. Cited by 67 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 7 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00345839 phase3completednot on this map

EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events

TypeinterventionalSponsorAmgenRan2006 to 2012Enrolled3,883ConditionsSecondary Hyperparathyroidism, Chronic Kidney DiseaseArmsCinacalcet, Placebo
3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 7 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Angiotensin-related genetic determinants of cardiovascular disease in patients undergoing hemodialysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019
    Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Type of arrhythmias and the risk of sudden cardiac death in dialysis patients: a systematic review and meta-analysis.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025
    Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

17 authors at 11 institutions in 6 countries.

David C WheelerUniversity College London, London, UK (D.C.W.).
Gerard M LondonHôpital Manhès, Paris, France (G.M.L.).
Patrick S ParfreyHealth Sciences Center St. John's, Newfoundland, Canada (P.S.P.).
Geoffrey A BlockDenver Nephrology, Denver, CO (G.A.B.).
Ricardo Correa-RotterInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico (R.C.R.).
Bastian DehmelAmgen, Inc, Thousand Oaks, CA (B.D., Y.K., W.G.G., M.L.T.).
Tilman B DrüekeInserm Unit 1088, UFR Médecine/Pharmacie, Université de Picardie, Amiens, France (T.B.D.).
Jürgen FloegeUniversitätsklinikum der RWTH Aachen, Aachen, Germany (F.).
Yumi KuboAmgen, Inc, Thousand Oaks, CA (B.D., Y.K., W.G.G., M.L.T.).
Kenneth W MahaffeyStanford University School of Medicine, Palo Alto, CA (K.W.M., S.A., G.M.C.).
William G GoodmanAmgen, Inc, Thousand Oaks, CA (B.D., Y.K., W.G.G., M.L.T.).
Sharon M MoeIndiana University School of Medicine, Roudebush Veterans Administration Medical Center, Indianapolis, IN (S.M.M.).
Marie-Louise TrotmanAmgen, Inc, Thousand Oaks, CA (B.D., Y.K., W.G.G., M.L.T.).
Safa AbdallaStanford University School of Medicine, Palo Alto, CA (K.W.M., S.A., G.M.C.).
Glenn M ChertowStanford University School of Medicine, Palo Alto, CA (K.W.M., S.A., G.M.C.).
Charles A HerzogHennepin County Medical Center, University of Minnesota, Minneapolis, MN (C.A.H.).
EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial Investigators
Amgen (United States) · USStanford University · USColorado Kidney Care · USIndiana University – Purdue University Indianapolis · USInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXPalo Alto University · USSt. John’s Health Sciences Centre · CAUniversitätsklinikum Aachen · DEUniversité de Picardie Jules Verne · FRUniversity College London · GBUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPremature cardiovascular disease limits the duration and quality of life on long-term hemodialysis. The objective of this study was to define the frequency of fatal and nonfatal cardiovascular events attributable to atherosclerotic and nonatherosclerotic mechanisms, risk factors for these events, and the effects of cinacalcet, using adjudicated data collected during the EValuation of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. METHODS AND

resultsEVOLVE was a randomized, double-blind, placebo-controlled clinical trial that randomized 3883 hemodialysis patients with moderate to severe secondary hyperparathyroidism to cinacalcet or matched placebo for up to 64 months. For this post hoc analysis, the outcome measure was fatal and nonfatal cardiovascular events reflecting atherosclerotic and nonatherosclerotic cardiovascular diseases. During the trial, 1518 patients experienced an adjudicated cardiovascular event, including 958 attributable to nonatherosclerotic disease. Of 1421 deaths during the trial, 768 (54%) were due to cardiovascular disease. Sudden death was the most frequent fatal cardiovascular event, accounting for 24.5% of overall mortality. Combining fatal and nonfatal cardiovascular events, randomization to cinacalcet reduced the rates of sudden death and heart failure. Patients randomized to cinacalcet experienced fewer nonatherosclerotic cardiovascular events (adjusted relative hazard 0.84, 95% CI 0.74 to 0.96), while the effect of cinacalcet on atherosclerotic events did not reach statistical significance.

conclusionsAccepting the limitations of post hoc analysis, any benefits of cinacalcet on cardiovascular disease in the context of hemodialysis may result from attenuation of nonatherosclerotic processes. CLINICAL TRIALS REGISTRATION: Unique identifier: NCT00345839. URL: ClinicalTrials.gov.

Indexed as

AtherosclerosisCalcimimetic AgentsCinacalcetDeath, Sudden, CardiacDouble-Blind MethodFemaleHeart FailureHumansHyperparathyroidism, SecondaryIntention to Treat AnalysisKidney Failure, ChronicMaleNaphthalenesRenal DialysisRisk FactorsSeverity of Illness IndexCalcimimetic AgentsCinacalcetNaphthalenesatherosclerosiscardiovascular diseasesheart failurekidneysudden death

Identifiers

PMID25404192
PMCPMC4338730
OpenAlexW2160986394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.